

Julie V. Philley, MD
President

The University of Texas at Tyler | UT Tyler Health Science Center
3900 University Blvd. | Tyler, Texas 75799

Academic Appointments

The University of Texas at Tyler

- **President** (2024–Present)
- Vice Provost (2021–2024)

The University of Texas at Tyler Health Science Center

- **Professor of Medicine** (2020–Present)
- Executive Vice President for Health Affairs (2021–2024)
- Isadore Roosth Endowed Chair (2019–2023)
- Chair of Medicine (2018–2021)
- Associate Professor of Medicine (2017–2020)
- Chief of Pulmonary & Critical Care Medicine (2016–2020)
- Assistant Professor of Medicine (2012–2017)

Education & Fellowship Training

Fellowship Training

Pulmonary & Critical Care Fellowship (2009–2012)

The University of Texas Southwestern Medical Center | Dallas, Texas

Mycobacteria Fellowship (2011)

National Jewish Health | Denver, Colorado

Residency Training

Internal Medicine Residency (2006–2009)

Johns Hopkins University / Sinai Hospital | Baltimore, Maryland

Education

Masters of Business Administration (2024)

Baylor University

Doctor of Medicine (2006)

The University of Texas Health Science Center at Houston | Houston, Texas

Bachelor of Science in Nursing (1999)

Texas Woman's University | Denton, Texas

Undergraduate Studies (1995)

Tyler Junior College | Tyler, Texas

Hospital Appointments

- UT Health East Texas (2018–Present)
- The University of Texas Health Science Center at Tyler (2012–Present)
- CHRISTUS Trinity Mother Frances (2014–2022)
- UT Southwestern Medical Center (2009–2012)
- Sinai Hospital, Baltimore, MD (2006–2009)

Licensure & Board Certifications

Medical Licensure

- State of Texas, Physician License No. N3244 (Active)

Board Certification

- American Board of Internal Medicine – Critical Care Medicine (2012–Present)
- American Board of Internal Medicine – Pulmonary Disease (2011–Present)
- American Board of Internal Medicine – Internal Medicine (2009–Present)

Board and Governance Service

UT Health East Texas

- Chair, Board of Directors (2024–Present)
- Member, Board of Directors (2021–2024)

Teaching Hospitals of Texas

- Executive Board Member (2024–Present)
- Member (2021–2024)

Council of Public University Presidents and Chancellors (CPUPC)

- Member (2024–Present)

Association of Public & Land-Grant Universities (APLU)

- Member (2024–Present)

East Texas Quality Care Network

- Chair, Board of Directors (2022–Present)

Hospice of East Texas

- Member, Board of Directors (2023–2025)

UT Health Tyler

- Chair, Board of Trustees (2022–2023)
- Vice Chair, Board of Trustees (2018–2020)

East Texas Medical Center Foundation

- Member, Board of Directors (2019–2024)

East Texas Crisis Center

- Chair, Board of Directors (2016)
- Member, Board of Directors (2013–2020)

Academic & Professional Service

Service to the University (*Selected*)

- Chair, MSRDP Board of Directors (2024–Present)
- Member, QEP Steering Committee (2024)
- Information Technology Governance Steering Committee (2023–Present)
- Institutional Audit Committee (2021–Present)
- Handbook of Operating Procedures Committee (2021–Present)
- MSRDP Board of Directors & Executive Committee (2021–2024)
- Compliance Committee (2020–Present)
- Faculty Compensation Committee (2019–Present)
- Chief of Staff (2019–2020)
- Academic Affiliation Committee (2018–2024)
- Medical Executive Committee (2017–2024)
- Chair, Faculty Senate (2016–2018)
- Member, Faculty Senate (2016–2018)

Editorial Activities

- Hospital Physician: Infectious Disease – Board Review: *Nontuberculous Mycobacterial Pulmonary Infection in Non-HIV Patients*. Volume 15, Part 7. 2014.

Journal Peer Review

- *CHEST* (2012–Present)
- *Clinical Pulmonary Medicine* (2012–2024)
- *BMJ* (2014–2024)
- *PLOS ONE* (2015)
- *American Journal of Microbiology* (2020)

National Committees and Advisory Service

- Bronchiectasis Research Registry Executive Committee (2019–2024)
- CHEST Foundation Bronchiectasis/NTM Review Panel (2019–2021)
- National Bronchiectasis Registry Committee (2019–2024)

Professional Memberships

- Teaching Hospitals of Texas (2012–Present)
- Texas Medical Association (2012–Present)
- American College of Physicians (2012–Present)
- American College of Chest Physicians (2012–Present)
- American Thoracic Society (2012–Present)
- Smith County Medical Society (2014–Present)
- European Respiratory Society (2014–2018)

Leadership Development

- Leadership Tyler – Catalyst 100, Season XIII (2025–2026)

Community Service

- Tyler Tomorrow Comprehensive Plan Steering Committee (2025–Present)
- Women's Symphony League (2018–Present)
- American Heart Association Circle of Red (2018–Present)
- Stewardship Committee, First Presbyterian Church (2018–2020)

Honors & Awards

2026

Texas Woman's University | Chancellor's Excellence Award
Women in Tyler | Women Laying the Foundation Award
Bethesda Health Clinic | Dr. Luke Society

2025

Tyler Junior College | Distinguished Alumni Award

2013

The University of Texas Health Science Center at Tyler | Will Avery Faculty of the Year Award

2009

Johns Hopkins University / Sinai Hospital

- Award for Humanism and Professionalism
- Resident of the Year
- Ambulatory Care Resident Award

2008

Johns Hopkins University / Sinai Hospital | Junior Resident of the Year

2007

Johns Hopkins University / Sinai Hospital | Intern of the Year

2006

The University of Texas Health Science Center at Houston | Hitoshi Nikaidoh Award for Humanism in Medicine

Teaching & Mentorship

Post-Doctoral Fellows

Bockgie Jung, PhD (2019–2024)

Clinical Teaching & Preceptorships

Pulmonary Medicine & Critical Care, UT Health East Texas (2018–Present)

Intensive Care for Family Medicine Residents, UT Health East Texas (2012–Present)

Research & Extramural Support

National Institutes of Health Support (Selected)

Philley JV, Investigator; Devine MS, Co-Investigator; Sigler C, Coordinator. Treatment of Patients With COVID-19 (CONTAIN Study). National Institutes of Health. 04/10/2020.

Vankayalapati R, PhD, Principal Investigator; **Philley JV**, MD, Consultant. NIH-CRDF Global (INDO-US VAP Phase 2). Identify Immunologic Markers of Persons at Highest Risk of Progression of Latent Tuberculosis Infection to Tuberculosis. Role: Consultant. 10/01/2019–09/30/2024.

Clinical Research Studies

Multi-National Comparison Analysis Using Quantitative Radiological Evaluation in *Mycobacterium avium* Complex Pulmonary Disease (MACPD).

Sponsor: PI-Initiated | **Role:** Principal Investigator | **Years:** 2017–2021

Determining the Effectiveness of Airway Clearance on Subjects With Bronchiectasis.

Sponsor: PI-Initiated | **Role:** Principal Investigator | **Years:** 2017–2023

Bronchiectasis Research Registry: A Consolidated Database of Non-Cystic Fibrosis Bronchiectasis Patients From Major Clinical and Research Institutions (Registry).

Sponsor: COPD Foundation | **Role:** Principal Investigator | **Years:** 2010–2024

Biospecimen Banking and Biomarker Validation for Lung Cancer Early Detection in a Cohort Receiving Low-Dose Helical Computed Tomography Screening (Registry).

Sponsor: MD Anderson Cancer Center | **Role:** Principal Investigator | **Years:** 2015–2025

Multicenter Randomized Pragmatic Clinical Trial Comparing Two- versus Three-Antibiotic Therapy for Pulmonary *Mycobacterium avium* Complex Disease.

Sponsor: Oregon Health & Science University / Patient-Centered Outcomes Research Institute | **Role:** Principal Investigator | **Years:** 2019–2023

Clinical Effectiveness of High-Frequency Chest Wall Oscillation (HFCWO) in a Bronchiectasis Population.

Sponsor: Electromed Incorporated | **Role:** Principal Investigator | **Years:** 2019–2023

A Phase 1 Multicenter Study to Measure the Pharmacokinetics of Oral Omadacycline in Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP).

Sponsor: Paratek Pharmaceuticals, Inc. | **Role:** Principal Investigator | **Years:** 2019–2023

Evaluation of High-Frequency Chest Wall Oscillation (HFCWO) Using the Vest® System for Treatment of Non-Cystic Fibrosis Bronchiectasis in the Home Setting.

Sponsor: Hill-Rom Company, Inc. | **Role:** Principal Investigator | **Years:** 2019–2023

Qualitative Interviews to Support Patient-Reported Outcome (PRO) Measurement Development in Patients With *Mycobacterium avium* Complex (MAC) or *Mycobacterium abscessus* (MABs) Lung Infection.

Sponsor: Insmmed Inc. | **Role:** Principal Investigator | **Years:** 2019–2023

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis: The WILLOW Study.

Sponsor: Insmmed Corporation | **Role:** Principal Investigator | **Years:** 2018–2023

Multiple Patient Program for Lamprene® (Clofazimine) for the Treatment of Nontuberculous Mycobacterial (NTM) Infections (Compassionate Use).

Sponsor: Novartis | **Role:** Principal Investigator | **Years:** 2017–2023

An Exploratory, Prospective, Open-Label Study of the Efficacy, Safety, and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily in Combination With Multidrug Treatment of *Mycobacterium abscessus* Lung Disease.

Sponsor: Insmmed Incorporated | **Role:** Principal Investigator | **Years:** 2016–2023

Use of Clofazimine for the Treatment of Nontuberculous Mycobacterial (NTM) Infections in Patients With Limited Therapeutic Options (Compassionate Use).

Sponsor: Novartis | **Role:** Principal Investigator | **Years:** 2015–2023

Clinical Disease, Treatment, and Outcomes for Patients Infected With *Mycobacterium abscessus* (Chart Review).

Sponsor: PI-Initiated | **Role:** Principal Investigator | **Years:** 2013–2023

Clinical Data Related to Estrogen in Women With Bronchiectasis With or Without Nontuberculous Mycobacterial (NTM) Disease.

Sponsor: PI-Initiated | **Role:** Principal Investigator | **Years:** 2022

Breast Cancer Gene Analysis in Patients With Non-Cystic Fibrosis Bronchiectasis.

Sponsor: PI-Initiated | **Role:** Principal Investigator | **Years:** 2017–2022

Circulating Inflammatory Biomarkers in Chronic Lung Disease Patients With or Without Nontuberculous Mycobacterial (NTM) Disease.

Sponsor: PI-Initiated | **Role:** Principal Investigator | **Years:** 2017–2022

Clofazimine in the Treatment of Pulmonary *Mycobacterium avium* Complex (MAC) Disease (MAC-CLOFAZ-001).

Sponsor: Novartis | **Role:** Principal Investigator | **Years:** 2016–2022

Breast Cancer Gene Analysis in Patients With Non-Cystic Fibrosis Bronchiectasis (Blood Draw).

Sponsor: PI-Initiated | **Role:** Principal Investigator | **Years:** 2014–2022

An Open-Label, Multicenter Study to Evaluate the Long-Term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency.

Sponsor: Grifols Therapeutics Inc. | **Role:** Sub-Investigator | **Years:** 2019–2021

Assessment of Anxiety and Depression in Non-Cystic Fibrosis Bronchiectasis Patients.

Sponsor: PI-Initiated | **Role:** Principal Investigator | **Years:** 2018–2021

Bedaquiline in Refractory *Mycobacterium avium* Complex and *Mycobacterium abscessus* Patients (Blood Draw).

Sponsor: PI-Initiated | **Role:** Principal Investigator | **Years:** 2013–2020

An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by *Mycobacterium avium* Complex (MAC) Refractory to Treatment (INS-312).

Role: Sub-Investigator | **Years:** 2015–2019

A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by *Mycobacterium avium* Complex (MAC) Refractory to Treatment (INS-212).

Role: Sub-Investigator | **Years:** 2015–2019

A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F) (Protocol VX17-445-103).

Role: Principal Investigator | **Years:** 2018

A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation (Protocol VX17-445-105).

Sponsor: Vertex Pharmaceuticals | **Role:** Principal Investigator | **Years:** 2018

A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis.

Sponsor: Mallinckrodt | **Role:** Principal Investigator | **Years:** 2018

A Phase IIA, Two-Part, Randomized, Multicenter, Multinational, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of BCT197 When Added to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Requiring Hospitalization in Adults (Protocol MBCT206).

Role: Sub-Investigator | **Years:** 2018

Circulating Inflammatory Biomarkers in Patients With Chronic Lung Disease With and Without Nontuberculous Mycobacterial (NTM) Lung Infection (Blood Draw).

Sponsor: PI-Initiated | **Role:** Principal Investigator | **Years:** 2013–2018

A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-Cystic Fibrosis Bronchiectasis Chronically Infected With *Pseudomonas aeruginosa*.

Sponsor: Zambon SpA | **Role:** Principal Investigator | **Years:** 2017

Liposomal Amikacin for Inhalation for the Treatment of Nontuberculous Mycobacterial (NTM) Infections (Compassionate Use Study).

Sponsor: Insmed Corporation | **Role:** Principal Investigator | **Years:** 2017

Long-Term Administration of Inhaled Mannitol in Cystic Fibrosis: A Safety and Efficacy Trial in Adult Subjects With Cystic Fibrosis (DPM-CF-303).

Role: Principal Investigator | **Years:** 2015–2017

A Multicenter, Randomized, Double-Blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha1-Proteinase Inhibitor (Human) Compared With Prolastin®-C in Subjects With Alpha1-Antitrypsin Deficiency.

Role: Sub-Investigator | **Years:** 2015–2017

A Phase IIA, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066 as Add-On Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.

Role: Sub-Investigator | **Years:** 2015–2017

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second

Allele With a CFTR Mutation Predicted to Have Residual Function (Protocol VX14-661-108).

Role: Principal Investigator | **Years:** 2015–2017

A Randomized, Double-Blind, Chronic Dosing (56-Week), Placebo-Controlled, Parallel-Group, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Two Doses of Benralizumab (MEDI-563) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (GALATHEA).

Role: Sub-Investigator | **Years:** 2014–2017

A 26-Week, Randomized, Active-Controlled Safety Study of Double-Blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma.

Role: Sub-Investigator | **Years:** 2014–2016

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With *Pseudomonas aeruginosa* in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including a 28-Day Open-Label Extension and Pharmacokinetic Substudy (ORBIT-3).

Role: Sub-Investigator | **Years:** 2014–2016

A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF).

Sponsor: Vertex Pharmaceuticals | **Role:** Principal Investigator

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With *Pseudomonas aeruginosa* in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including a 28-Day Open-Label Extension (ORBIT-4).

Role: Sub-Investigator | **Years:** 2014–2016

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of BMS-986020 in Subjects With Idiopathic Pulmonary Fibrosis (Clinical Protocol IM136003).

Sponsor: Bristol-Myers Squibb Pharmaceutical Research Institute | **Role:** Sub-Investigator | **Years:** 2013–2016

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg Twice Daily Intermittently Administered for 28 Days On/28 Days Off or 14 Days On/14 Days Off Versus Placebo to Evaluate Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.

Role: Sub-Investigator | **Years:** 2013–2016

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-3 (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) (SUN101-301).

Role: Sub-Investigator | **Years:** 2015

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg Twice Daily Intermittently Administered for 28 Days On/28 Days Off or 14 Days On/14 Days Off Versus Placebo to Evaluate Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.

Role: Sub-Investigator | **Years:** 2015

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents With Oral Corticosteroid-Dependent Asthma (TROPOS).

Role: Sub-Investigator | **Years:** 2013–2014

Peer-Reviewed Publications

McBride S, Rose D, Baham A, Haas B, Byrd T, Cox SM, **Philley JV**. A Roadmap to Innovation and Data Science for Researchers, Faculty, and Students. *Comput Inform Nurs*. 2026. Apr 17.

Dennison JB, Gendarme S, Kettner NM, Godoy MCB, **Philley JV**, Antonoff MB, Adams M, Grainger A, Shersher DD, Putnam JB, Lee C, Ryu RK, Fan AC, Chouaid C, Maitre B, Carballo N, Ostrin EJ, Hanash S. The LEAP Study: A Multicenter Biospecimen and Imaging Resource for Lung Cancer Screening. *Cancer Epidemiology, Biomarkers & Prevention*. 2026.

Boorgula G, Gumbo T, Singh S, McShane P, **Philley JV**, Srivastava S. Omadacycline Drug Susceptibility Testing for Nontuberculous Mycobacteria Using Oxyrase to Overcome Challenges With Drug Degradation. *Tuberculosis*. 2024.

Boyd J, Grecco M, Beyer M, Flume P, O'Donnell A, **Philley JV**, Rutland C, Drew H. Empowering Health Care Professionals Through Online Training in Non-Cystic Fibrosis Bronchiectasis and Nontuberculous Mycobacterial Lung Disease Patient Care. *Chest*. 2024.

Singh S, Gumbo T, Boorgula GD, Thomas TA, **Philley JV**, Srivastava S. Omadacycline Pharmacokinetics/Pharmacodynamics and Efficacy Against Multidrug-Resistant *Mycobacterium tuberculosis* in the Hollow Fiber System Model. *Antimicrobial Agents and Chemotherapy*. 2024.

Singh S, Boorgula GD, Aryal S, **Philley JV**, Gumbo T, Srivastava S. Sarecycline Pharmacokinetics/Pharmacodynamics in the Hollow-Fibre Model of *Mycobacterium avium* Complex: So Near and Yet So Far. *Journal of Antimicrobial Chemotherapy*. 2024.

Singh S, Gumbo T, Boorgula GD, Thomas T, **Phillely JV**, Srivastava S. Omadacycline Pharmacokinetics/Pharmacodynamics and Efficacy Against Multidrug-Resistant *Mycobacterium tuberculosis* in the Hollow Fiber System Model. *Antimicrobial Agents and Chemotherapy*. 2023.

Yoon H, Li Y, Goldfeld K, Cobb G, Sturm-Reganato C, Ostrosky-Zeichner L, Jayaweera D, **Phillely JV**, Desruisseaux M, Keller M, Hochman J, Pirofski L-A, Ortigoza M, Cronstein B, Keeling D, Rappoport N, Saraga J, Holahan J, Andela R, Ford A. COVID-19 Convalescent Plasma Therapy: Long-Term Implications. *Open Forum Infectious Diseases*. 2023.

Seigel SR, Griffith DE, **Phillely JV**, Brown-Elliott B, Brunton A, Sullivan P, Fuss C, Strnad L, Wallace RJ, Winthrop KL. Open-Label Trial of Amikacin Liposome Inhalation Suspension in *Mycobacterium abscessus* Lung Disease. *Chest*. 2023.

El Ghali A, Morrisette T, Alosaimy S, Lucas K, Tupayachi-Ortiz M, Vemula R, Wadle C, **Phillely JV**, et al. Long-Term Evaluation of Clinical Success and Safety of Omadacycline in Nontuberculous Mycobacteria Infections: A Retrospective, Multicenter Cohort of Real-World Health Outcomes. *Antimicrobial Agents and Chemotherapy*. 2023.

Singh S, Wang JY, Heysell SK, McShane PJ, Wadle C, Shankar P, Huang HL, Pasipanodya J, Boorgula GD, **Phillely JV**, et al. Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber Model and Clinical Validation of Efficacy to Treat Pulmonary *Mycobacterium abscessus* Disease. *International Journal of Antimicrobial Agents*. 2023.

Flume P, Basavaraj A, García B, Winthrop K, Mango E, Daley C, **Phillely JV**, Henkle E, O'Donnell A. Towards Development of Evidence to Inform Recommendations for the Evaluation and Management of Bronchiectasis. *Respiratory Medicine*. 2023.

Asif H, Rahaghi FF, Ohsumi A, **Phillely J**, et al. Management of Nontuberculous Mycobacteria in Lung Transplant Cases: An International Delphi Study. *ERJ Open Research*. 2023.

Ku JH, Siegel SAR, **Phillely JV**, Schipper P, Thanawala R, Hendrick MA, Sigler C, Strnad L, McShane PJ, Griffith DE, et al. Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States. *Chest*. 2022.

Srivastava S, Pasipanodya JG, Heysell SK, Boorgula GD, Gumbo T, McShane PJ, **Phillely JV**. An Overview of Drugs for the Treatment of *Mycobacterium kansasii* Pulmonary Disease. *Journal of Global Antimicrobial Resistance*. 2022.

Jung BG, Dean K, Wadle C, Samten B, Tripathi D, Wallace RJ Jr, Brown-Elliott BA, Tucker T, Idell S, **Phillely JV**, Vankayalapati R. Decreased Interleukin-1 Family Cytokine Production in Patients With Nontuberculous Mycobacterial Lung Disease. *Microbiology Spectrum*. 2022.

Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, **Phillely JV**, et al.

CONTAIN: Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. *JAMA Internal Medicine*. 2022.

Jung BG, Dean K, Samten B, Wallace RJ Jr., Brown-Elliott BA, Tucker TA, Idell S, **Philley JV**, Vankayalapati R. Early IL-17A Production Helps Establish *Mycobacterium intracellulare* Infection in Mice. *PLOS Pathogens*. 2022.

Morrisette T, Alosaimy S, Lagnf A, **Philley JV**, et al. 1082. Real-World Experience With Omadacycline for Nontuberculous Mycobacterial Infections: A Multicenter Evaluation. *Open Forum Infectious Diseases*. 2021.

Metersky ML, Choate R; Bronchiectasis and NTM Research Registry Investigators. The Association of Long-Term Macrolide Therapy and Nontuberculous Mycobacterial Culture Positivity in Patients With Bronchiectasis. *Chest*. 2021.

McShane PJ, **Philley JV**, Prieto DA, Aksamit TR. Global Attitudes of Health Care Providers About Aerosolized Airway Clearance Therapy in Bronchiectasis Patients During the Coronavirus Disease 2019 Pandemic. *Chronic Obstructive Pulmonary Diseases*. 2021.

Asif H, Rahaghi FF, Ohsumi A, **Philley JV**, et al. Recommendations for Management of Nontuberculous Mycobacterial (NTM) in Lung Transplant Recipients: An International Delphi Study. *American Journal of Respiratory and Critical Care Medicine*. 2021.

Cook A, Sigler C, Allen L, Peters JA, Guthrie C, Marroquin M, Ndetan H, Singh KP, Murry J, Norwood S, **Philley JV**. Burnout and Anxiety Among Trauma Nursing Specialties in a Rural Level I Trauma Center. *Journal of Trauma Nursing*. 2021.

Morrisette T, Alosaimy S, **Philley JV**, Wadle C, Howard C, Webb AJ, Veve MP, Barger ML, Bouchard J, Gore TW, Lagnf AM, Ansari I, Mejia-Chew C, Cohen KA, Rybak MJ. Preliminary, Real-World, Multicenter Experience With Omadacycline for *Mycobacterium abscessus* Infections. *Open Forum Infectious Diseases*. 2021.

Despotes KA, Choate R, Addrizzo-Harris D, Aksamit TR, Barker A, Basavaraj A, Daley CL, Eden E, DiMango A, Fennelly K, **Philley JV**, et al. Nutrition and Markers of Disease Severity in Patients With Bronchiectasis. *Chronic Obstructive Pulmonary Diseases*. 2020.

Kannan A, **Philley JV**, Hertweck KL, Ndetan H, Singh KP, Sivakumar S, Wells RB, Vadlamudi RK, Dasgupta S. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and Is Traceable in the Circulating Extracellular Vesicles. *Scientific Reports*. 2019.

Olusola P, Banerjee HN, **Philley JV**, Dasgupta S. Human Papillomavirus-Associated Cervical Cancer and Health Disparities. *Cells*. 2019.

Philley JV, Griffith DE. Medical Management of Pulmonary Nontuberculous Mycobacterial Disease. *Thoracic Surgery Clinics*. 2019.

Philley JV, Kannan A, Olusola P, McGaha P, Singh KP, Samten B, Griffith DE, Dasgupta S. Microbiome Diversity in Sputum of Nontuberculous Mycobacteria Infected Women With a History of Breast Cancer. *Cellular Physiology and Biochemistry*. 2019.

Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, **Philley JV**, et al. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by *Mycobacterium avium* Complex (CONVERT): A Prospective, Open-Label, Randomized Study. *American Journal of Respiratory and Critical Care Medicine*. 2018.

Philley JV, Hertweck KL, Kannan A, Brown-Elliott BA, Wallace RJ Jr, Kurdowska A, Ndetan H, Singh KP, Miller EJ, Griffith DE, Dasgupta S. Sputum Detection of Predisposing Genetic Mutations in Women With Pulmonary Nontuberculous Mycobacterial Disease. *Scientific Reports*. 2018.

Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Cardoso-Leão S, Garcia MJ, Vasireddy S, Turenne CY, Griffith DE, **Philley JV**, Niemann S, Wallace RJ, Cirillo DM. *Mycobacterium abscessus*, a Taxonomic Puzzle. *International Journal of Systematic and Evolutionary Microbiology*. 2018.

Griffith DE, **Philley JV**. The New “Hesitation Blues”: Initiating *Mycobacterium avium* Complex Lung Disease Therapy. *European Respiratory Journal*. 2017.

Philley JV, Kannan A, Griffith DE, Devine MS, Benwill JL, Wallace RJ Jr, Brown-Elliott BA, Thakkar F, Taskar V, Fox JG, Alqaid A, Bains H, Gupta S, Dasgupta S. Exosome Secretome and Mediated Signaling in Breast Cancer Patients With Nontuberculous Mycobacterial Disease. *Oncotarget*. 2017.

Brown-Elliott BA, **Philley JV**, Griffith DE, Thakkar F, Wallace RJ Jr. In Vitro Susceptibility Testing of Bedaquiline Against *Mycobacterium avium* Complex. *Antimicrobial Agents and Chemotherapy*. 2017.

Alexander DC, Vasireddy R, Vasireddy S, **Philley JV**, Brown-Elliott BA, Perry BJ, Griffith DE, Benwill JL, Cameron AD, Wallace RJ Jr. Emergence of *mmpT5* Variants During Bedaquiline Treatment of *Mycobacterium intracellulare* Lung Disease. *Journal of Clinical Microbiology*. 2017.

Brown-Elliott BA, **Philley JV**, Griffith DE, Thakkar F, Wallace RJ Jr. In Vitro Susceptibility Testing of Bedaquiline Against *Mycobacterium avium* Complex. *Antimicrobial Agents and Chemotherapy*. 2017.

Brown-Elliott BA, **Philley JV**. Rapidly Growing Mycobacteria. *Microbiology Spectrum*. 2017.

Philley JV, DeGroote MA, Honda JR, Chan MM, Kasperbauer S, Walter ND, Chan ED. Treatment of Nontuberculous Mycobacterial Lung Disease. *Current Treatment Options in Infectious Diseases*. 2016.

Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Leão SC, Garcia MJ, Vasireddy S, Turenne CY, Griffith DE, **Philley JV**, et al. Emended Description of *Mycobacterium abscessus*, *Mycobacterium abscessus* subsp. *abscessus* and *Mycobacterium abscessus* subsp. *bolletii* and Designation of *Mycobacterium abscessus* subsp. *massiliense* Comb. Nov. *International Journal of Systematic and Evolutionary Microbiology*. 2016.

Philley JV, Kannan A, Qin W, Sauter ER, Ikebe M, Hertweck KL, Troyer DA, Semmes OJ, Dasgupta S. Complex-I Alteration and Enhanced Mitochondrial Fusion Are Associated With Prostate Cancer Progression. *Journal of Cellular Physiology*. 2016.

Philley JV, Kannan A, Dasgupta S. MDA-9/Syntenin Control. *Journal of Cellular Physiology*. 2016.

Griffith DE, Adjemian J, Brown-Elliott BA, Prevots DR, **Philley JV**, Olivier KN, Wallace RJ Jr. Reply: Cure Not Possible, by Definition. *American Journal of Respiratory and Critical Care Medicine*. 2015.

Griffith DE, Adjemian J, Brown-Elliott BA, **Philley JV**, Prevots DR, Gaston C, Olivier KN, Wallace RJ Jr. Semiquantitative Culture Analysis During Therapy for *Mycobacterium avium* Complex Lung Disease. *American Journal of Respiratory and Critical Care Medicine*. 2015.

Philley JV, Griffith DE. Impulse Oscillometry and Bronchiectasis: We Still Haven't Found What We're Looking For? *Annals of the American Thoracic Society*. 2015.

Philley JV, Griffith DE. Treatment of Slowly Growing Mycobacteria. *Clinics in Chest Medicine*. 2015.

Philley JV, Griffith DE. Management of Nontuberculous Mycobacterial (NTM) Lung Disease. *Seminars in Respiratory and Critical Care Medicine*. 2013.

Philley JV, Wallace RJ, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE. Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease. *Chest*. 2015.

Griffith DE, **Philley JV**, Brown-Elliott BA, Benwill J, Shepherd S, York D, Wallace RJ Jr. The Significance of *Mycobacterium abscessus* subsp. *abscessus* Isolation During *Mycobacterium avium* Complex (MAC) Lung Disease Therapy. *Chest*. 2014.

Wallace RJ Jr, Brown-Elliott BA, McNulty S, **Philley JV**, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE. Macrolide/Azalide Therapy for Nodular/Bronchiectatic *Mycobacterium avium* Complex Lung Disease. *Chest*. 2014.

Canadian Association of Pathologists Telepathology Guidelines Committee, Bernard C, Chandrakanth SA, Cornell IS, Dalton J, Evans A, Garcia BM, Godin C, Godlewski M, Jansen GH, Kabani A, Louahia S, Manning L, Maung R, Moore L, **Philley JV**, et al. Guidelines From the Canadian Association of Pathologists for Establishing a Telepathology Service for Anatomic Pathology Using Whole-Slide Imaging. *Journal of Pathology Informatics*. 2014.

Griffith DE, **Philley JV**, Aksamit T. Nontuberculous Mycobacterial (NTM) Lung Disease: The Top Ten Essentials. *Respiratory Medicine*. 2014.

Babb T, Levine B, **Philley JV**. ICU-Acquired Weakness: An Extension of the Effects of Bed Rest. *American Journal of Respiratory and Critical Care Medicine*. 2012.

Books/Chapters

Philley, JV. “Medical Management of Pulmonary Nontuberculous Mycobacterial Disease.” *Surgery for Pulmonary Mycobacterial Disease*, by John D. Mitchell, 1st ed., vol. 29, Elsevier, 2019, pp. 65–76.

Philley, JV. “Nontuberculous Mycobacterial Disease in Transplant Recipients.” *Principles and Practice of Transplant Infectious Diseases*, by Amar Safdar, Springer, 2019, pp. 503–517.

Philley, JV. “Antimycobacterial Consideration in Transplantation Including Drug Non-Susceptibility and Resistance: Tuberculosis and Nontuberculous Mycobacterial Disease.” *Principles and Practice of Transplant Infectious Diseases*, by Amar Safdar, Springer, 2019, pp. 1003-1017.

Philley, JV. “Diseases Due to Nontuberculous Mycobacteria.” *Fishman’s: Pulmonary Diseases and Disorders* by Michael A. Grippi, MD, 5th ed., vol. 2, McGraw Hill Education, 2015, pp. 2032-2038.

Selected Abstracts

Stassek L, Bushnell D, Eckburg P, Henkle E, Winthrop K, **Philley JV**, Huber J, Castañeda-Ruiz B, Long J, Krause K, Easom E. *Qualitative Interviews to Develop the MACrO2 Patient-Reported Outcome Measure in Treatment-Refractory Mycobacterium avium Complex Lung Disease (TR-MAC-LD)*. Poster presented at: NTM Conference; Colorado State University; Fort Collins, CO. May 27–30, 2025. Poster No. 73.

Bushnell DM, Stassek L, Smith A, Henkle E, Winthrop K, **Philley JV**, Easom E, Connolly L, Huber J, Castañeda-Ruiz B, Long J, Krause K, Eckburg PB. *Validation of the MACrO2 Patient-Reported Outcome (PRO) Measure in Treatment-Refractory Mycobacterium avium Complex Lung Disease (TR-MAC-LD)*. Poster presented at: NTM Conference; Colorado State University; Fort Collins, CO. May 27–30, 2025. Poster No. 71.

Bushnell DM, Stassek L, Smith A, **Philley JV**, Henkle E, Winthrop K, Easom E, Connolly L, Huber J, Castañeda-Ruiz B, Long J, Krause K, Eckburg PB. *Validation of the Quality of Life-Bronchiectasis (QOL-B) Respiratory Domain Patient-Reported Outcome (PRO) Measure in Treatment-Refractory Mycobacterium avium Complex Lung Disease (TR-MAC-LD)*. Poster presented at: NTM Conference; Colorado State University; Fort Collins, CO. May 27–30, 2025. Poster No. 72.

Farahani L, McShane PJ, Drake T, Brown-Elliott BA, **Philley JV**, Wallace RJ Jr, Griffith DE, Kasperbauer SH. *Bedaquiline Treatment as Salvage Therapy for Nontuberculous Mycobacterial Pulmonary Disease*. Presented at: American Thoracic Society International Conference; 2023. Abstract A4248.

McShane PJ, Wilsey RN, Koch TN, Dean KT, Terrell MM, Dohanich ER, Drake T, **Philley JV**, Honda JR. *AFB Culture Results of the Home Environment of Patients with Nontuberculous Mycobacterial Lung Disease*. Poster presented at: The University of Texas Health Science Center at Tyler; Tyler, TX. (Year, if available.)

Hawkins JA, Siegel SAR, Henkle E, Ali J, Miller W, McShane PJ, **Philley JV**, Daley CL, Griffith DE, Winthrop KL. *Clofazimine in the Treatment of Pulmonary Mycobacterium avium Complex (MAC) Disease*. Presented at: American Thoracic Society International Conference, C27 – NTM/Bronchiectasis Rapid Fire Posters, RAPiD Poster Discussion Session; May 21, 2024.

Singh S, Gumbo T, Boorgula GD, Thomas TA, **Philley JV**, Srivastava S. Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant *Mycobacterium tuberculosis* in the hollow fiber system model. *Antimicrob Agents Chemother*. 2024 Feb 7

Singh S, Boorgula GD, Aryal S, **Philley JV**, Gumbo T, Srivastava S. Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of *Mycobacterium avium* complex: so near and yet so far. *J Antimicrob Chemother*. 2024 Jan 3

Hawkins JA, Siegel SAR, Henkle E, Ali J, Miller W, McShane PJ, **Philley JV**, Daley CL, Griffith DE, Winthrop KL. *Clofazimine in the Treatment of Pulmonary Mycobacterium avium Complex (MAC) Disease*. Presented at: American Thoracic Society International Conference (ATS); 2024.

McShane PJ, Wilsey RN, Koch TN, Dean KT, Terrell MM, Dohanich ER, Drake T, **Philley JV**, Honda JR. *Recovery and Identification of Mycobacterium abscessus and Mycobacterium avium Complex from Home Environmental Samples of Patients with Nontuberculous Mycobacterial Lung Disease*. Presented at: World Bronchiectasis Conference (WBC); 2024.

Siegel SAR, Griffith DE, **Philley JV**, Brown-Elliott BA, Brunton AE, Sullivan PE, Fuss C, Strnad L, Wallace RJ Jr, Winthrop KL. *Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease*. *Chest*. 2023.

Flume PA, Basavaraj A, Garcia B, Winthrop K, Di Mango E, Daley CL, **Philley JV**, et al. *Towards Development of Evidence to Inform Recommendations for the Evaluation and Management of Bronchiectasis*. *Respiratory Medicine*. 2023.

Asif H, Rahaghi FF, Ohsumi A, **Philley JV**, Emtiazjoo A, Hiramata T, Baker AW, Shu CC, Silveira F, Poulin V, Philley JV, et al. *Management of Nontuberculous Mycobacteria in Lung Transplant Cases: An International Delphi Study*. *ERJ Open Research*. 2023.

Farahani L, McShane PJ, Drake T, Brown-Elliott BA, **Philley JV**, Wallace RJ Jr, Griffith DE, Kasperbauer SH. *Bedaquiline Treatment as Salvage Therapy for Nontuberculous Mycobacterial Pulmonary Disease*. Presented at: American Thoracic Society International Conference (ATS); 2023.

Yao B, Sarva K, Florova G, Hibbard R, Devine M, **Philley JV**, Idell S, McPherson DD, Komissarov A. *Fibrinolysis and Inflammation in Convalescent Plasma-Treated COVID-19 Patients*. Presented at: American Thoracic Society International Conference (ATS); 2023.

Hassanin EH, Terada R, Alvarado C, Wadle C, Swindall R, Cook A, Devine MS, **Philley JV**. *The Use of Bruton Tyrosine Kinase Inhibitors in Severe COVID-19 Patients*. Presented at: American Thoracic Society International Conference (ATS); 2022.

Henkle E, **Philley JV**, Addrizzo-Harris DJ, Daley CL, Griffith DE, Aksamit TR, Swenson C, Ruoss SJ, Marras TK, Brunton AE, Winthrop KL. *Self-Reported Symptom and Adverse Event Profiles in Macrolide-Based Oral Treatment of Mycobacterium avium Complex Pulmonary Disease*. Presented at: American Thoracic Society International Conference (ATS); 2022.

Terada R, Greenlee K, Drake T, Dean K, **Philley JV**, Jung BG, McShane PJ. *Immune Profiles in Bronchiectasis Patients With and Without MAC Lung Disease*. Presented at: American Thoracic Society International Conference (ATS); 2022.

Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, **Philley JV**, et al. *Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial*. JAMA Internal Medicine. 2022.

Jung BG, Dean K, Samten B, Wallace RJ Jr, Brown-Elliott BA, Tucker TA, Idell S, **Philley JV**, Vankayalapati R. *Early IL-17A Production Helps Establish Mycobacterium intracellulare Infection in Mice*. Presented at: Keystone Symposia; 2022.

Terada RS, Dean K, Greenlee KL, Drake TJ, **Philley JV**, Jung BG, McShane PJ. *Immune Profiles in Bronchiectasis Patients With and Without MAC Lung Disease*. Presented at: American Thoracic Society International Conference (ATS); 2022.

Henkle E, **Philley JV**, Addrizzo-Harris DJ, Daley CL, Griffith DE, Aksamit TR, Swenson C, Ruoss SJ, Marras TK, Brunton AE, Winthrop KL. *Self-Reported Symptom and Adverse Event Profiles in Macrolide-Based Oral Treatment of Mycobacterium avium Complex Pulmonary Disease*. Presented at: American Thoracic Society International Conference (ATS); 2022.

Philley JV, Deck DH, Sirbu A, Das AF, Serio AW, Brenner R, Berman G, Winthrop K. *Omadacycline in Mycobacterium abscessus Pulmonary Disease*. Presented at: Colorado Mycobacteria Conference; 2022.

Asif H, Rahaghi FF, Ohsumi A, **Philley JV**, Emtiazjoo A, Hiramata T, Baker AW, Shu CC, Silveira F, Poulin V, et al. *Recommendations for Management of Nontuberculous Mycobacterial (NTM) in Lung Transplant Recipients: An International Delphi Study*. Presented at: American Thoracic Society International Conference (ATS); 2021. Abstract A3945.

Henkle E, Quittner AL, Brunton AE, Marras TK, Flume P, Addrizzo-Harris D, Ali J, **Philley JV**, Winthrop KL. *Respiratory Symptoms and Health Perception Improve Rapidly in Patients Treated for Pulmonary Mycobacterium avium Complex Disease*. Presented at: American Thoracic Society International Conference (ATS); 2021.

Ku J, Siegel SAR, Schipper P, Tieu B, Hendrick A, Sigler C, Strnad L, Fuss C, Caccitolo J, **Philley JV**. *Surgical Outcome of Resectional Thoracic Surgery for the Treatment of Nontuberculous Mycobacterial*

Pulmonary Disease in 98 U.S. Patients. Presented at: American Thoracic Society International Conference (ATS); 2020.

Philley JV, Guthrie CM, Sigler C, Solomon GM, Kirkpatrick D. *Correlation of Anxiety in Patients With Non-Cystic Fibrosis Bronchiectasis.* Presented at: American College of Chest Physicians (CHEST) Annual Meeting; 2019.

Sigler C, Guthrie CM, Griffith DE, Singh KP, Ndetan H, **Philley JV**. *Determining the Effectiveness of Airway Clearance in Subjects With Non-Cystic Fibrosis Bronchiectasis.* Presented at: New York University; 2018.

Philley JV, Devine MS, Calhoun KM, Thakkar F, Brown-Elliott BA, Wallace RJ Jr, Griffith DE. *Macrolide-Resistant Mycobacterium avium Complex Pulmonary Disease Treated With Bedaquiline.* Presented at: American Thoracic Society International Conference (ATS); 2018. Abstract A5917.

Siegel SAR, **Philley JV**, Thakkar F, Devine MS, Ku J, Caccitolo J, Winthrop KL. *Video-Assisted Thoracoscopic Surgery (VATS) for Nontuberculous Mycobacterial Lung Disease in the Setting of Structural Lung Disease.* Presented at: American Thoracic Society International Conference (ATS); 2018. Abstract A2612.

Philley JV, Guthrie C, Whitehead S, Cook A, Benwill J, Brown-Elliott BA, Wallace RJ, Griffith DE. *A Possible Association Between Breast Cancer, Bronchiectasis and Nontuberculous Mycobacterial (NTM) Lung Disease.* Presented at: European Respiratory Society (ERS) International Congress; 2014.

Philley JV, Iakhiaeva E, McNulty S, Brown-Elliott BA, Falkinham JO III, Williams MD, Vasireddy R, Vasireddy S, Wilson RW, Griffith DE, Turenne C, Benwill J, Stout JE, Wallace RJ Jr. *Clinical and Laboratory Features of Respiratory Isolates of Mycobacterium chimaera.* Presented at: American Thoracic Society International Conference (ATS); 2014.

Griffith DE, **Philley JV**, Brown-Elliott BA, Wallace RJ Jr. *Isolation of Mycobacterium abscessus From Patients With Mycobacterium avium Complex (MAC) Lung Disease.* Presented at: European Respiratory Society (ERS) International Congress; 2013.

Arauco-Brown A, **Philley JV**, Battaile JT. *Inhaled Corticosteroid Use in COPD Is Not Associated With an Increased Likelihood of Airway Colonization With Nontuberculous Mycobacteria.* Presented at: American Thoracic Society International Conference (ATS); 2013.

Weldon C, **Philley JV**, Hlavarty A, Menard R. *What's in Your Supplement? Sarcoidosis Precipitated by Over-the-Counter Hormone Supplementation.* Presented at: American Thoracic Society International Conference (ATS); 2013.

Philley JV, Newton CM, Battaile JT. *Gastric Acid Suppression May Influence the Likelihood of Isolating Nontuberculous Mycobacteria From the Airways of Individuals With COPD.* Presented at: American College of Chest Physicians (CHEST) Annual Meeting; 2011.

Phillely JV, Battaile JT. *Isolation of Nontuberculous Mycobacteria From Airway Culture Is Associated With an Increased Likelihood of COPD Exacerbation Within One Year*. Presented at: American Thoracic Society International Conference (ATS); 2011.

Phillely JV, Battaile JT. *Airway Colonization With Multiple Strains of Nontuberculous Mycobacteria Is More Likely in Patients With Severe COPD*. Presented at: American College of Chest Physicians (CHEST) Annual Meeting; 2010.

Educational Media and Digital Scholarship

Phillely JV, Leitman P. *Kathryn Raaker's World – NTM*. Educational video. January 13, 2019.

Phillely JV. *Mycobacterial Lung Infection: A Big Name for a Serious Problem*. Educational video. University of Texas Health Science Center at Tyler; June 1, 2016.

Phillely JV. *When Pneumonia Walks*. Educational video. University of Texas Health Science Center at Tyler; October 19, 2013.

Phillely JV. *Pulmonary Hypertension*. Educational video. University of Texas Health Science Center at Tyler; October 7, 2012.

Invited Lectures, Presentations & Academic Speaking Engagements (Selected)

2026

Tyler Area Chamber of Commerce
Panelist, *Future Leaders of Tyler*

United Way of Tyler/Smith County
Guest Speaker, Leadership Dinner

2025

Texas Higher Education Coordinating Board
Panelist, *Building a Future-Ready Texas: Moving from Ideas to Impact*

ACHE Education Event
Partnerships for Success: Public Health and Health System Collaboration

Baylor University
Speaker, *Public Private Partnerships: Sense of Cents*

East Texas Leadership Summit

2024

The University of Texas Southwestern Medical Center
Internal Medicine Grand Rounds

Texas Primary Care Consortium (TPCC) Convening

2023

San Juan City Hospital, Puerto Rico
Invited Grand Rounds, *NTM-LD: Improving Diagnosis, Individualized Treatment, and Adherence*

Louisiana State University, Shreveport, LA
Invited Grand Rounds, *NTM-LD: Improving Diagnosis, Individualized Treatment, and Adherence*

6th World Bronchiectasis Conference, New York, NY
To Treat or Not to Treat: Contemporary Considerations in Treating MAC Lung Disease

6th World Bronchiectasis Conference, New York, NY
Airway Clearance in Bronchiectasis: An Interactive Session

France Foundation
NTM Lung Disease: A Case-Based Approach

2022

The University of Texas Southwestern Medical Center
Invited Grand Rounds, *NTM Lung Disease: A Case-Based Approach*

University of Connecticut
A Case-Based Approach: NTM Lung Disease

2021

American Thoracic Society International Conference, San Diego, CA
Casirivimab with Imdevimab, a Cocktail of Two Antibodies Against SARS-CoV-2, in the Outpatient Setting: Phase 3 Efficacy and Safety Results

2020

Norton Institute Lung Transplant Symposium, Scottsdale, AZ
Mycobacterium avium Complex: Diagnosis and Treatment

2019–2022

Oregon Health & Science University, Portland, OR
Research Speaker, *UTHSCT NTM Research Update*

2018–2022

American Thoracic Society International Conference
Invited Speaker, Postgraduate Course: *Nontuberculous Mycobacteria (NTM)*

2018–2021

New York University, New York, NY
Invited Speaker, NTM Symposium

2019

American College of Chest Physicians (CHEST), Los Angeles, CA
CHEST Immersion: Nontuberculous Mycobacterial Disease

The University of Texas Health Science Center at Tyler / Gaylord Texas Resort & Convention Center,
Grapevine, TX
NTM & Bronchiectasis National Physician/Patient Conference

2018

NTM Symposium, San Antonio Marriott Rivercenter, San Antonio, TX
Nontuberculous Mycobacteria: Best Practices in Diagnosing and Managing NTM